8-KOther EventsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Corporate Update (Jun 7, 2018)

Filed June 7, 2018For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) announced on June 7, 2018, that it successfully priced and entered into an underwriting agreement to issue $600 million in senior unsecured notes due in 2028. These notes carry a coupon rate of 4.300%. This action indicates the company's strategy to raise capital, likely to fund ongoing operations, research and development, or potential strategic initiatives. The issuance was made under an effective registration statement previously filed with the SEC, suggesting a well-planned financial maneuver. Investors should note that this debt issuance adds to the company's leverage. While the specific use of proceeds is not detailed in this 8-K, the fixed 4.300% interest rate on these notes provides a predictable cost of capital for the next decade. The company's ability to secure this funding at this rate reflects its creditworthiness and market confidence. The inclusion of the underwriting agreement as an exhibit provides transparency into the terms of the debt offering.

Key Highlights

  • 1Edwards Lifesciences priced and entered into an agreement to issue $600 million in senior unsecured notes.
  • 2The notes have a fixed interest rate of 4.300% and mature in 2028.
  • 3The debt issuance is subject to certain conditions, as outlined in the underwriting agreement.
  • 4The notes will be unsecured, meaning they are not backed by specific company assets.
  • 5The issuance was made pursuant to a previously filed effective registration statement.
  • 6The underwriting agreement was entered into on June 6, 2018.
  • 7Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC are acting as representatives for the underwriters.

Frequently Asked Questions

This 8-K filing announces that Edwards Lifesciences has priced and entered into an underwriting agreement to issue $600 million of senior unsecured notes due in 2028. It serves as a public disclosure of this significant debt financing event.

Issuing $600 million in notes will increase Edwards Lifesciences' total debt and leverage. The fixed 4.300% interest rate will add a predictable annual interest expense for the next decade. Investors should monitor the company's debt-to-equity ratio and interest coverage ratios following this issuance.

The 4.300% interest rate represents the cost of borrowing for Edwards Lifesciences on these notes. The 2028 maturity date means the principal amount is due to be repaid in ten years. This long-term financing provides capital for an extended period, and the fixed rate offers protection against rising interest rates.

The specific details of the underwriting agreement are available as Exhibit 1.1 to this 8-K filing, which is incorporated by reference. Investors can review this document for comprehensive terms and conditions related to the issuance.